Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Infectious Disease Epidemiology Department, London School of Hygiene and Tropical Medicine.
J Glob Antimicrob Resist. 2022 Jun;29:176-184. doi: 10.1016/j.jgar.2022.03.001. Epub 2022 Mar 11.
Enterobacteriaceae are common pathogens causing bloodstream infection (BSI) in sub-Saharan Africa and frequently express third-generation cephalosporin (3GC) resistance; however, the impact of 3GC resistance on clinical outcomes is rarely studied.
We conducted a single-site prospective cohort study at Tygerberg Hospital, Cape Town, South Africa to examine the feasibility of measuring impacts of 3GC resistance in Enterobacteriaceae BSI. We included patients with 3GC-susceptible and 3GC-resistant BSIs and matched each BSI patient to two uninfected patients. We determined the concordance of initial antibiotic treatment with the corresponding isolate's susceptibility profile. We performed exploratory impact analysis using multivariable regression models.
Between 1 June 2017 and 31 January 2018, we matched 177 Enterobacteriaceae BSI patients to 347 uninfected patients. Among these BSIs, 35% were phenotypically 3GC resistant. Parameters describing clinical comorbidity showed strong associations with mortality. We found that 18% of 3GC-R and 3% of 3GC-S BSI patient received non-concordant initial therapy. In multivariable Cox regression, we found a mortality impact over their matched patients for both 3GC-R (cause-specific hazard ratio 23.77; 95% CI 5.12-110.3) and 3GC-S (HR 7.49; 95%CI 3.08-18.19) BSI. There was a nonsignificant ratio of these ratios (HR 3.18; 95% CI 0.54-18.70), limited by the small sample size.
This form of impact estimation was feasible in one hospital in South Africa where 3GC-R status was associated with non-concordant initial antibiotic treatment. There was a possible increase in mortality among individuals with 3GC-resistant Enterobacteriaceae, but with broad confidence intervals. These analytical approaches could be applied to larger datasets to improve precision of estimates.
肠杆菌科是导致撒哈拉以南非洲血流感染(BSI)的常见病原体,通常对第三代头孢菌素(3GC)具有耐药性;然而,3GC 耐药性对临床结局的影响很少被研究。
我们在南非开普敦泰格伯格医院进行了一项单站点前瞻性队列研究,以检验测量肠杆菌科血流感染中 3GC 耐药性影响的可行性。我们纳入了对 3GC 敏感和 3GC 耐药性 BSI 的患者,并将每位 BSI 患者与两名未感染的患者相匹配。我们确定初始抗生素治疗与相应分离株的药敏谱是否一致。我们使用多变量回归模型进行了探索性影响分析。
在 2017 年 6 月 1 日至 2018 年 1 月 31 日期间,我们将 177 例肠杆菌科血流感染患者与 347 名未感染患者相匹配。在这些 BSI 中,35%的表型为 3GC 耐药。描述临床合并症的参数与死亡率有很强的相关性。我们发现,3GC-R 和 3GC-S BSI 患者中,分别有 18%和 3%接受了非一致的初始治疗。在多变量 Cox 回归中,我们发现 3GC-R(特异性病因危险比 23.77;95%置信区间 5.12-110.3)和 3GC-S(HR 7.49;95%CI 3.08-18.19)BSI 的死亡率均高于其匹配患者。由于样本量小,这些比值的比值无统计学意义(HR 3.18;95%CI 0.54-18.70)。
在南非的一家医院中,这种影响估计形式是可行的,3GC-R 状态与初始抗生素治疗不一致有关。3GC 耐药肠杆菌科感染患者的死亡率可能有所增加,但置信区间较宽。这些分析方法可以应用于更大的数据集,以提高估计的精度。